PATH vs PYXS · P/E 19, rev $1.61B vs rev $2.8M
Uipath Inc (PATH) versus Pyxis Oncology Inc (PYXS) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Pyxis Oncology Inc (PYXS) is a biotechnology company listed on NASDAQ.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported PYXS revenue for 2025-09-30 was $2.8M. Net income was -$22.0M. Revenue was up 0.0% from 2025-06-30 to 2025-09-30. PYXS currently screens at market cap $109.6M.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. PYXS currently screens at market cap $109.6M.
Not investment advice. Open the PATH and PYXS stock pages for the full models.
Not investment advice.